Company Diamyd Medical AB (publ) Nasdaq Stockholm
Equities
SE0005162880
Biotechnology & Medical Research
Business Summary
Sales per Business
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical Products
100.0
%
| 0 | 100.0 % | 1 | 100.0 % | +20.26% |
Sales per region
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Sweden
100.0
%
| 0 | 100.0 % | 1 | 100.0 % | +20.26% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Ulf Hannelius
CEO | Chief Executive Officer | 49 | 10/16/10 |
Founder | 83 | 01/96/01 | |
Anna Styrud
DFI | Director of Finance/CFO | 63 | 01/10/01 |
Christoph Nowak
CTO | Chief Tech/Sci/R&D Officer | 38 | 01/21/01 |
Anton Lindqvist
CTO | Chief Tech/Sci/R&D Officer | 44 | 01/13/01 |
Martina Widman
COO | Chief Operating Officer | 43 | 01/16/01 |
Markus Jerling
CTO | Chief Tech/Sci/R&D Officer | 72 | - |
Eva Karlström
LAW | General Counsel | 60 | 01/20/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 83 | 01/96/01 | |
Director/Board Member | 63 | 01/12/01 | |
Director/Board Member | 52 | 28/21/28 | |
Director/Board Member | 76 | 01/17/01 | |
Director/Board Member | 54 | 01/09/01 | |
Mark Atkinson
BRD | Director/Board Member | 63 | 15/18/15 |
Karin Rosen
BRD | Director/Board Member | 57 | 10/23/10 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 2,741,630 | 0 | 0 | 72.91 % |
Stock B | 1 | 92,206,366 | 69,230,180 ( 75.08 %) | 0 |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
-1.65% | 103B | |
+6.75% | 101B | |
+6.70% | 23.07B | |
-12.60% | 22.23B | |
-5.24% | 18.05B | |
-39.98% | 17.18B | |
-10.17% | 16.94B | |
+6.12% | 14.07B | |
+35.47% | 12.35B |